Profile data is unavailable for this security.
About the company
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
- Revenue in USD (TTM)0.00
- Net income in USD-53.37m
- Incorporated2011
- Employees54.00
- LocationLeap Therapeutics Inc47 Thorndike St Ste B1-1CAMBRIDGE 02141-1799United StatesUSA
- Phone+1 (617) 252-4343
- Fax+1 (302) 636-5454
- Websitehttps://www.leaptx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celularity Inc | 14.79m | -181.41m | 66.22m | 225.00 | -- | 1.95 | -- | 4.48 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
Instil Bio Inc | 0.00 | -123.32m | 66.47m | 49.00 | -- | 0.3229 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
Intensity Therapeutics Inc | 0.00 | -15.13m | 66.50m | 5.00 | -- | 6.84 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Sangamo Therapeutics Inc | 18.76m | -328.05m | 66.82m | 405.00 | -- | 1.16 | -- | 3.56 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Allakos Inc | 0.00 | -214.44m | 67.29m | 131.00 | -- | 0.6414 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
enVVeno Medical Corp | 0.00 | -22.12m | 67.32m | 31.00 | -- | 1.59 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Kronos Bio Inc | 7.59m | -116.39m | 67.91m | 61.00 | -- | 0.4957 | -- | 8.95 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
Medicinova Inc | 1.00m | -8.41m | 68.66m | 13.00 | -- | 1.15 | -- | 68.66 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
FibroGen Inc | 167.49m | -240.46m | 68.74m | 486.00 | -- | -- | -- | 0.4104 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Bioatla Inc | 0.00 | -119.24m | 68.81m | 65.00 | -- | 1.38 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Leap Therapeutics Inc | 0.00 | -53.37m | 70.02m | 54.00 | -- | 0.9891 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 70.57m | 47.00 | -- | 1.77 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
Cognition Therapeutics Inc | 0.00 | -28.77m | 70.90m | 25.00 | -- | 2.45 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Prenetics Global Ltd | 22.25m | -49.97m | 71.17m | 320.00 | -- | 0.3107 | -- | 3.20 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
Spero Therapeutics Inc | 110.98m | 23.40m | 71.53m | 46.00 | 3.14 | 0.7416 | 3.02 | 0.6446 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Anixa Biosciences Inc | 0.00 | -11.60m | 72.65m | 4.00 | -- | 3.08 | -- | -- | -0.3694 | -0.3694 | 0.00 | 0.7381 | 0.00 | -- | -- | 0.00 | -45.19 | -59.69 | -46.33 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Baker Bros. Advisors LPas of 31 Mar 2024 | 1.17m | 3.06% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 911.94k | 2.38% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 856.10k | 2.24% |
Citadel Advisors LLCas of 31 Mar 2024 | 711.32k | 1.86% |
Balyasny Asset Management LPas of 31 Mar 2024 | 670.54k | 1.75% |
Adage Capital Management LPas of 31 Mar 2024 | 480.00k | 1.25% |
683 Capital Management LLCas of 31 Mar 2024 | 450.00k | 1.18% |
Simplify Asset Management, Inc.as of 31 Mar 2024 | 375.98k | 0.98% |
Acuta Capital Partners LLCas of 31 Mar 2024 | 354.17k | 0.93% |
Acadian Asset Management LLCas of 31 Mar 2024 | 282.41k | 0.74% |